Have you seen our new ‘How I treat…’ features? Become a member (it’s free!) and discover the latest advice from fellow clinicians here >>>

Zejula® significantly improves progression-free survival in ovarian cancer patients

Written by Mike Gregg, Future Science Group

The results have been announced for GlaxoSmithKline plc (GSK, Middlesex, UK) Phase III PRIMA study of Zejula® (niraparib) for patients with ovarian cancer in the first-line maintenance setting. The results have been positive with patients demonstrating significant improvements in progression-free survival (PFS) regardless of their biomarker status. PRIMA (ENGOT-OV26/GOG-3012) is a Phase III randomized, double blind, placebo-controlled study of Zejula as a maintenance therapy in patients who have first-line ovarian cancer following platinum-based chemotherapy. The aims of the study were to assess the efficacy of Zejula as a maintenance treatment, this was achieved by monitoring patient’s PFS. The patients selected...

To view this content, please register now for access

It's completely free